Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha

Clinical Rheumatology

Volumn 28, Issue 4, 2009, Pages 421-426

  Elbek, Osman ^a   Uyar, Meral ^a   AydIn, Neriman ^a   Börekçi, Sermin ^a   Bayram, Nazan ^a   Bayram, Hasan ^a   Dikensoy, Öner ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Adverse event; Screening; TNFalpha blocking agent; Tuberculosis

Indexed keywords

CHLOROQUINE; COLCHICINE; CORTICOSTEROID; ETANERCEPT; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; METHOTREXATE; PYRAZINAMIDE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; ASCITES; BACTERIUM CULTURE; COUGHING; EOSINOPHILIA; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; LUNG DISEASE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERITONITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCAR; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS; TURKEY (REPUBLIC);

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; FEMALE; HUMANS; IMMUNOGLOBULIN G; ISONIAZID; MALE; METHOTREXATE; MIDDLE AGED; MYCOBACTERIUM BOVIS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61549143375     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-1067-x     Document Type: Article

References (31)

1. Cho H, Lasco TM, Allen SS et al (2005) Recombinant guinea pig tumor necrosis factor alpha stimulates the expression of interleukin-12 and the inhibition of Mycobacterium tuberculosis growth in macrophages. Infect Immun 73:1367-1376
2. Mutlu GM, Mutlu EA, Bellmeyer A et al (2006) Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy. Am J Med 119:639-646
3. Vordermeier HM (1995) T-cell recognition of mycobacterial antigens. Eur Respir J Suppl 20(Suppl):657-667
4. Flynn JL, Goldstein MM, Chan J et al (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572
5. Stenger S (2005) Immunological control of tuberculosis: Role of tumour necrosis factor and more. Ann Rheum Dis 64(Suppl 4):24-28
6. Engele M, Stössel E, Castiglione K et al (2002) Induction of TNF in human alveolar macrophages as a potential evasion mechanism of virulent Mycobacterium tuberculosis. J Immunol 168:1328-1337
7. Schiff MH, Burmester GR, Kent JD et al (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889-894
8. Kiter G, Uçan ES (2001) Prevention of tuberculosis. Toraks 2:85-90
9. WHO Global Health Atlas (2007) Turkey. http://www.who.int/GlobalAtlas/ predefinedReports/TB/index.asp?strSelectedCountry=tur Accessed 20 Aug 2007
10. Ozsahin SL, Akkurt I, Ozdemir L et al (2006) Are official reports sufficient? Official registration rates of patients with tuberculosis in Sivas, Middle Anatolia. Public Health 120:434-440
11. Şakar A, Göktalay T, Daǧyildizi L et al (2003) A tuberculosis screening among school children in Manisa Province. Toraks 4:38-42
12. Tanrikulu Ç, Abakay A, Abakay Ö et al (2006) Tuberculosis screening results made at primary schools in Cizre. Tuberk Toraks 54:336-340
13. Bozkurt AI, Bozkurt N (2001) Gaziantep kent merkezi'nde beş yaşindan küçük çocuklarda BCG aşilama oranlari. Anadolu Tip Dergisi 3:163-167
14. Lasco TM, Cassone L, Kamohara H et al (2005) Evaluating the role of tumor necrosis factor-alpha in experimental pulmonary tuberculosis in the guinea pig. Tuberculosis (Edinb) 85:245-258
15. Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
16. Gardam MA, Keystone EC, Menzies R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 3:148-155
17. Toussirot E, Wendling D (2004) The use of TNF-alpha blocking agents in rheumatoid arthritis: An overview. Expert Opin Pharmacother 5:581-594
18. Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2:602-610
19. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766-1772
20. Provenzano G, Ferrante MC, Simon G (2005) TB screening and anti-TNF alpha treatment. Thorax 60:613
21. Bargman C (2004) TNF inhibitors and tuberculosis. Am J Nurs 104:15-16
22. Roberts L, McColl GJ (2004) Tumour necrosis factor inhibitors: Risks and benefits in patients with rheumatoid arthritis. Intern Med J 34:687-693
23. Gomez-Reino JJ, Carmona L, Valverde VR et al (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 48:2122-2127
24. Askling J, Fored CM, Brandt L et al (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52:1986-1992
25. Dunlop H (2004) Infliximab (Remicade) and etanercept (Enbrel): Serious infections and tuberculosis. CMAJ 171:992-993
26. Imaizumi K, Sugishita M, Usui M et al (2006) Pulmonary infectious complications associated with anti-TNF alpha therapy (infliximab) for rheumatoid arthritis. Intern Med 45:685-688
27. Hanta I, Ozbek S, Kuleci S et al (2008) The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: Experience with 192 patients. Clin Rheumatol 27:1083-1086
28. Desai SB, Furst DE (2006) Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 20:757-790
29. Wallis RS, Broder MS, Wong JY et al (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261-1265
30. British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60:800-805
31. Joven BE, Almodovar R, Galindo M et al (2006) Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response? Ann Rheum Dis 65:699